Új kezelési lehetoség a 2-es típusú diabetes terápiájában: DPP-4-gátlók (sitagliptin)

Translated title of the contribution: A new therapeutic class for the therapy of type 2 diabetes: DPP-4 inhibitors (sitagliptin)

Tatjána Ábel, J. Fehér

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Type 2 diabetes is a very common worldvide disorder. A good glycemic controll is reduce the rates of diabetes associated microvascular and possibly macrovascular complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin demonstrate an incretin based, glucose-dependent actions with low risk of hypoglycemia and no weight gain during the treatment of patients with type 2 diabetes.

Original languageHungarian
Pages (from-to)1012-1016
Number of pages5
JournalOrvosi Hetilap
Volume151
Issue number25
DOIs
Publication statusPublished - Jun 1 2010

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Type 2 Diabetes Mellitus
Incretins
Hypoglycemia
Weight Gain
Glucose
Therapeutics
Sitagliptin Phosphate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Új kezelési lehetoség a 2-es típusú diabetes terápiájában : DPP-4-gátlók (sitagliptin). / Ábel, Tatjána; Fehér, J.

In: Orvosi Hetilap, Vol. 151, No. 25, 01.06.2010, p. 1012-1016.

Research output: Contribution to journalArticle

@article{f8a05e6df37e4784bb45af83bdb7c331,
title = "{\'U}j kezel{\'e}si lehetos{\'e}g a 2-es t{\'i}pus{\'u} diabetes ter{\'a}pi{\'a}j{\'a}ban: DPP-4-g{\'a}tl{\'o}k (sitagliptin)",
abstract = "Type 2 diabetes is a very common worldvide disorder. A good glycemic controll is reduce the rates of diabetes associated microvascular and possibly macrovascular complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin demonstrate an incretin based, glucose-dependent actions with low risk of hypoglycemia and no weight gain during the treatment of patients with type 2 diabetes.",
keywords = "Incretin, Sitagliptin, Therapy",
author = "Tatj{\'a}na {\'A}bel and J. Feh{\'e}r",
year = "2010",
month = "6",
day = "1",
doi = "10.1556/OH.2010.28910",
language = "Hungarian",
volume = "151",
pages = "1012--1016",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "25",

}

TY - JOUR

T1 - Új kezelési lehetoség a 2-es típusú diabetes terápiájában

T2 - DPP-4-gátlók (sitagliptin)

AU - Ábel, Tatjána

AU - Fehér, J.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Type 2 diabetes is a very common worldvide disorder. A good glycemic controll is reduce the rates of diabetes associated microvascular and possibly macrovascular complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin demonstrate an incretin based, glucose-dependent actions with low risk of hypoglycemia and no weight gain during the treatment of patients with type 2 diabetes.

AB - Type 2 diabetes is a very common worldvide disorder. A good glycemic controll is reduce the rates of diabetes associated microvascular and possibly macrovascular complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin demonstrate an incretin based, glucose-dependent actions with low risk of hypoglycemia and no weight gain during the treatment of patients with type 2 diabetes.

KW - Incretin

KW - Sitagliptin

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=77953208938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953208938&partnerID=8YFLogxK

U2 - 10.1556/OH.2010.28910

DO - 10.1556/OH.2010.28910

M3 - Article

C2 - 20519186

AN - SCOPUS:77953208938

VL - 151

SP - 1012

EP - 1016

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 25

ER -